Business Context and Reporting Period
This Form 6-K filing by GSK plc covers the month of September 2026. The report serves as a transaction notification regarding a purchase of company securities by a Person Discharging Managerial Responsibilities (PDMR).
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It is strictly a regulatory disclosure of a specific securities transaction.
Material Changes
No material changes to the company's financial position or operations are reported in this document. The filing details a single transaction involving the acquisition of American Depositary Shares (ADS) by Maya Martinez-Davis, President of GSK US, on September 8, 2026.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It includes a standard corporate description stating GSK is a global biopharma company focused on uniting science, technology, and talent.
Investor Verification Points
- Transaction Details: Verify the acquisition of 9.837 ADS by Maya Martinez-Davis at a price of $48.5400 per share.
- Transaction Context: Confirm the purchase was made within the GSK Executive Supplemental Savings Plan account.
- Market Data: Cross-reference the transaction date (September 8, 2026) and price with New York Stock Exchange (XNYS) records.
- Financial Absence: Note that this filing does not contain quarterly or annual financial results; investors should refer to Form 20-F for comprehensive financial data.